[
    [
        {
            "time": "2018-03-15",
            "original_text": "Why You Should Buy ABBV Stock for Income and Value",
            "features": {
                "keywords": [
                    "buy",
                    "ABBV",
                    "income",
                    "value"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why You Should Buy ABBV Stock for Income and Value",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "FDA puts partial hold on clinical trials of AbbVie's cancer drug",
            "features": {
                "keywords": [
                    "FDA",
                    "hold",
                    "clinical trials",
                    "cancer drug"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "FDA puts partial hold on clinical trials of AbbVie's cancer drug",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-04-11",
            "original_text": "AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma",
            "features": {
                "keywords": [
                    "AbbVie",
                    "stock down",
                    "FDA",
                    "hold",
                    "venetoclax",
                    "multiple myeloma"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-04-12",
            "original_text": "AbbVie Provides Update on VENCLEXTA速/VENCLYXTO速 (venetoclax) Multiple Myeloma Program",
            "features": {
                "keywords": [
                    "AbbVie",
                    "update",
                    "VENCLEXTA",
                    "VENCLYXTO",
                    "venetoclax",
                    "multiple myeloma"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Provides Update on VENCLEXTA速/VENCLYXTO速 (venetoclax) Multiple Myeloma Program",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-13",
            "original_text": "AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know",
            "features": {
                "keywords": [
                    "AbbVie",
                    "stock sinks",
                    "market gains"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]